Publication Date:
1995-10-20
Description:
In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA- SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Blaese, R M -- Culver, K W -- Miller, A D -- Carter, C S -- Fleisher, T -- Clerici, M -- Shearer, G -- Chang, L -- Chiang, Y -- Tolstoshev, P -- Greenblatt, J J -- Rosenberg, S A -- Klein, H -- Berger, M -- Mullen, C A -- Ramsey, W J -- Muul, L -- Morgan, R A -- Anderson, W F -- New York, N.Y. -- Science. 1995 Oct 20;270(5235):475-80.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉National Center for Human Genome Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/7570001" target="_blank"〉PubMed〈/a〉
Keywords:
Adenosine Deaminase/administration &
;
dosage/blood/*deficiency/*genetics/therapeutic use
;
Antibody Formation
;
Base Sequence
;
Child
;
Child, Preschool
;
Female
;
Follow-Up Studies
;
Gene Expression
;
*Gene Transfer Techniques
;
*Genetic Therapy
;
Genetic Vectors
;
Humans
;
Immunity, Cellular
;
Lymphocyte Count
;
Lymphocyte Transfusion
;
Lymphocytes/enzymology
;
Molecular Sequence Data
;
Severe Combined Immunodeficiency/enzymology/immunology/*therapy
;
*T-Lymphocytes/enzymology/immunology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
